Overview

Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2024-03-28

Target enrollment:

Participant gender:

Summary

Study to determine the safety and tolerability profile of durvalumab with platinum (cisplatin or carboplatin) plus etoposide (EP) as first-line treatment in participants with extensive-stage small-cell lung cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Carboplatin
Durvalumab
Etoposide